Biosimilar Switches: What Your Insurer Can Change and What You Can Appeal

A letter arrives saying your plan will no longer cover the biologic you have been taking for years, and that you will be moved to a biosimilar version on a specific date. For most people with Crohn's disease or ulcerative colitis, the first question is whether they have any say in it. The answer depends on what federal law says about the products themselves, what your state's pharmacy laws allow, and what your plan contract and appeal rights permit. Knowing which of those is driving your letter tells you whether an appeal has a realistic path.

What your insurer is actually changing

A biosimilar is a biologic that is highly similar to an already-approved reference product with no clinically meaningful differences in safety, purity, or potency. The FDA describes biosimilars as given at the same strength and dosage and carrying the same treatment risks and benefits as the original biologic. Infliximab-dyyb, marketed as Inflectra, is labeled as biosimilar to Remicade and carries the same Crohn's disease and ulcerative colitis indications, the same 5 mg/kg induction schedule at weeks 0, 2, and 6, and the same boxed warning for serious infections and malignancy.

When an insurer moves you for cost reasons rather than clinical ones, this is called non-medical switching. The dose and infusion or injection schedule usually stay the same. What often changes alongside it are the practical details: the specialty pharmacy that ships your product, the infusion site your plan considers in-network, the copay assistance program you were enrolled in, and the autoinjector you have learned to use. Those logistics are frequently where appeals succeed, because they are plan-specific rather than product-specific.

Interchangeability and substitution depend on state law

Federal law defines an interchangeable biologic as one that may be substituted for the reference product without the intervention of the prescriber. That federal designation does not by itself authorize a pharmacist to swap your product. Dispensing is regulated at the state level, and states differ substantially in what they require. A 2025 analysis of state substitution statutes found that 43 states require patient notification at dispensing, 10 require the pharmacist to notify the prescribing physician within five days, and 5 require express prescriber authorization before substitution. States with fewer restrictions had higher biosimilar market share.

This distinction matters for how you respond. Pharmacy-level substitution of an interchangeable product is a state-law question, and a prescriber writing "dispense as written" or equivalent brand-medically-necessary language is the mechanism that blocks it where state law permits. A formulary change by your insurer is a different matter. That is a coverage decision under your benefit contract, contested through the plan's exception and appeal process rather than through the pharmacy.

What the switching evidence shows

Appeals are stronger when they rest on your specific clinical history rather than general objections to biosimilars, because the published switching evidence is reassuring. The NOR-SWITCH trial randomized 482 patients on stable originator infliximab to continue or switch to CT-P13, and found disease worsening in 26 percent of those continuing the originator versus 30 percent of switchers, meeting the prespecified non-inferiority margin. In British Columbia's mandatory infliximab switch, continuation at 12 months was 94.9 percent in the biosimilar group versus 90.1 percent in the originator group. The province's later adalimumab switch showed treatment persistence at 30 months of 88.2 percent for biosimilars versus 83.7 percent for the originator.

One documented phenomenon is worth naming. A study of non-medical infliximab switching found a temporary decline in patient-reported disease control at week 16 that resolved by week 32, while objective biomarkers stayed comparable between switchers and non-switchers. Symptom worsening after a switch is real to the person experiencing it, and objective monitoring separates a nocebo response from genuine loss of response.

The appeal rights you actually have

If your plan denies continued coverage of your current biologic, that denial is an adverse benefit determination. Under the ERISA claims rules, the plan must give you the specific reasons for the denial and a description of its review procedures, and group health plan participants get at least 180 days to appeal. HealthCare.gov confirms the same 180-day internal appeal window and notes that insurers must respond within 15 days for prior authorization requests, 30 days for services already received, and 72 hours for urgent care cases. If the internal appeal fails, you have four months from the final determination to request external review, and the insurer is legally required to accept the external reviewer's decision.

Marketplace plans must also run a formulary exception process, with standard decisions within 72 hours and expedited decisions within 24 hours when a delay could seriously jeopardize your health or ability to regain maximum function. Medicare Part D runs a parallel process requiring an oral or written supporting statement from your prescriber explaining why formulary alternatives would be ineffective or harmful, with expedited determinations due within 24 hours of receiving that statement.

Building the documentation an appeal needs

Every one of those processes turns on a prescriber statement grounded in your history, so the record you supply determines how strong that statement is. Assemble three categories of evidence before the deadline.

• Your prior therapy list with start dates, stop dates, and the specific reason each one ended, including primary non-response, secondary loss of response, antibody formation, or intolerance
• Objective markers over time, including C-reactive protein, fecal calprotectin, endoscopic findings, and drug trough levels or antidrug antibody results if measured
• Documented product-specific issues, such as injection site reactions, infusion reactions, or a device you cannot physically operate

Timing matters as much as content. One study of biologic dose escalation found that approval took a median of 7 days without an appeal and 29 days when an appeal was required, with longer delays associated with reduced likelihood of CRP improvement. In pediatric IBD, prior authorization was associated with delays of 10.2 to 24.6 days in biologic initiation and a 14.1 percent increased likelihood of corticosteroid dependence at 90 days. Filing before your current supply runs out keeps you from choosing between an unwanted product and a gap in therapy.

Most patients who go through an insurer-driven biosimilar switch do fine, and the appeal that matters is usually narrower than "I want to stay on my brand." A prior infusion reaction to a specific formulation, a documented antibody history, a device you cannot operate, or a switch that would push your infusions out of network are concrete, documentable reasons a plan can act on. The patients who get the outcome they want are the ones whose treatment timeline is written down before the letter arrives.